Printer Friendly
The Free Library
14,757,244 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Biora AB Report for the First Half Year 2000.


Business Editors

MALMO, Sweden--(BUSINESS WIRE)--Aug. 18, 2000

                 Report for the first half year 2000

                            Biora AB (publ)

                                                        www.biora.com

                              Half year   Half year      Full year
                                 2000        1999           1999

Sales, SEK millions              43.6        37.5           73.6

Operating loss, SEK millions   - 39.4      - 45.4         - 91.8

Net loss, SEK millions         - 37.9      - 42.2         - 86.7


-- Rickard Soderberg new President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  

-- Sales during the first half year of 2000 increased by 16

percent to SEK SEK

In currencies, this is the abbreviation for the Swedish Krona.

Notes:
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion.
 43.6 million (compared to SEK 37.5 million

during the same period in 1999). The increase occurred

primarily in the U S market.

-- Sales during the second quarter 2000 increased by 11 percent

to SEK 22.5 million (compared to SEK 20.3 million in 1999).

-- Premixed version of Emdogain, Emdogain(R)Gel, for treatment of

periodontal disease Periodontal Disease Definition

Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where
, launched in Europe.

-- The indication to use Emdogain to replace knocked-out teeth

launched in Europe in June.

-- The Swedish Industrial Fund has granted a conditional loan of

SEK 15 million for a Bio-Ex project.

Biora develops, manufactures and sells biologically based products primarily for use in the treatment of diseases of the oral cavity oral cavity
n.
The part of the mouth behind the teeth and gums that is bounded above by the hard and soft palates and below by the tongue and the mucous membrane connecting it with the inner part of the mandible.
. The principal product, Emdogain(R), which is approved for sale in Europe, North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere.  and Japan, regenerates naturally the supporting structure lost by the tooth due to periodontal disease. Biora's American Depository Shares are listed on the Nasdaq National Market in the US and Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries.  in Sweden.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 18, 2000
Words:252
Previous Article:ADVISORY/Neiman Marcus Edition Thunderbird Unveiled.
Next Article:Media Alert: Security Expert Available for Interviews Can Discuss How New Strain of the Malicious 'I Love You Virus' Can Sweep Away Private Passwords.
Topics:



Related Articles
Biora's Principal Product Emdogain Approved By FDA For Minimally Invasive Surgical Treatment of Periodontitis.
Biora AB Issues Half Year Report.
Biora AB Malmo, Sweden Releases Q3 Report.
Year End Report 1999 for Biora AB.
Rickard Soderberg new CEO for Biora AB.
Biora Increases Its Focus On the Dental Market.
Altered Production Process for Japan.
Biora AB Report for the First Half Year 2001.
RIVALS LENDING HELPING HAND.(News)
ARNOLD VETOES SCHOOL BILLS TOLERANCE IS KEY WITH BOTH PLANS.(News)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles